European Society for Medical Oncology Congress

The latest news from ESMO, including researcher interviews and physician perspective.


Meeting News Coverage

Financial toxicity associated with poorer quality of life, survival outcomes

October 11, 2016
COPENHAGEN, Denmark — Patients who experienced worsening financial burden after cancer diagnosis experienced poorer quality of life and an…
Meeting News Coverage

Selumetinib plus docetaxel fails to extend survival in KRAS–mutant NSCLC

October 11, 2016
COPENHAGEN, Denmark — The addition of selumetinib to second-line docetaxel did not improve outcomes among patients with KRAS–mutant…
Meeting News Coverage

Custirsen fails to improve survival in castration-resistant prostate cancer

October 11, 2016
COPENHAGEN, Denmark — The addition of custirsen to cabazitaxel and prednisone did not significantly extended OS in previously treated patients…
Meeting News CoveragePerspective

First-line nivolumab fails to prolong PFS for advanced PD-L1–positive NSCLC

October 11, 2016
COPENHAGEN, Denmark — Nivolumab did not significantly extend PFS compared with investigator’s choice of platinum-doublet chemotherapy in…
Meeting News CoveragePerspective

Cabozantinib extends PFS in metastatic renal cell carcinoma

October 10, 2016
COPENHAGEN, Denmark — Cabozantinib significantly prolonged PFS compared with sunitinib among poor- and intermediate-risk patients with…
Meeting News Coverage

Standard neoadjuvant chemotherapy improves OS, RFS in soft tissue sarcoma

October 10, 2016
COPENHAGEN, Denmark — Neoadjuvant chemotherapy with three full-dose courses of an anthracycline plus ifosfamide improved OS and RFS compared…
Meeting News CoveragePerspective

Adjuvant sunitinib extends DFS in high-risk renal cell carcinoma

October 10, 2016
COPENHAGEN, Denmark — Adjuvant treatment with sunitinib significantly prolonged DFS compared with placebo among patients with locoregional…
Meeting News CoveragePerspective

Pembrolizumab active in cisplatin-ineligible advanced urothelial cancer

October 10, 2016
COPENHAGEN, Denmark — First-line pembrolizumab demonstrated considerable antitumor activity in patients with advanced unresectable or…
Meeting News CoveragePerspective

Nivolumab may improve patient-reported outcomes in HNSCC

October 10, 2016
COPENHAGEN, Denmark — Patient-reported outcomes and symptoms stabilized or improved in patients with recurrent or metastatic head and neck…
Meeting News CoveragePerspective

Nintedanib improves PFS, not OS, in refractory, metastatic colorectal cancer

October 10, 2016
COPENHAGEN, Denmark — The addition of nintedanib to best supportive care appeared safe and significantly extended PFS in patients with…